MedTrace Logo

Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon

NCT01477281 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2011-11-22

No results posted yet for this study

Summary

The objective is to evaluate the effectiveness of the safety of Daflon in decreasing symptoms resulting from chronic venous insufficiency when compared with Daflon.

Conditions

  • Chronic Venous Insufficiency
  • Disease

Interventions

DRUG

Daflon

Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).

DRUG

Venaflon (Diosmin and Hesperidin)

Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).

Sponsors & Collaborators

  • Laboratório Teuto Brasileiro S/A

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-07-31
Completion
2012-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01477281 on ClinicalTrials.gov